Search

everythinglearnresearchcommunity

for

Search:↓

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.

The new ELISA method is reliable and eco-friendly for checking the quality of Pueraria candollei.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Blocking interferon-gamma helps prevent and treat hair loss in Alopecia Areata.

Hair and nail cells share similar proteins, indicating a common differentiation pathway.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

Blocking the Wnt pathway could lead to new treatments for cancer and tissue repair but requires careful development to avoid side effects.

EGFR-targeting cancer drugs can cause skin rashes and other side effects.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Cholesteatoma shows abnormal and increased EGF receptor expression, indicating its rapid growth.

Trichohyalin is also found in the outer layers of normal human skin.

Dupilumab can both heal and cause hair loss.

Omalizumab may cause hair loss.

Ptprq has multiple forms that change during inner ear development.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

K42 and K124 keratins are only found in horse hoof lamellae.

Mogamulizumab can cause hair loss and skin rashes.

Ustekinumab might work for severe psoriasis, but more research is needed to be sure.

IL-4 and IL-13 might play a role in a type of hair loss similar to alopecia areata.

Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.

Panitumumab can cause excessive ear hair growth.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Some drugs can cause permanent hair loss, though it's rare.

Gray hair can potentially be reversed, leading to new treatments.

Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.